Back to News
Market Impact: 0.32
Radformation Receives USFDA 510(k) Clearance for OptiPlan Automated VMAT Planning
Source: Business Wire
Healthcare & BiotechTechnology & InnovationRegulation & LegislationProduct Launches
Radformation received FDA 510(k) clearance for OptiPlan, enabling U.S. radiation oncology clinics to adopt its automated volumetric modulated arc therapy (VMAT) treatment-planning technology. The clearance is a meaningful regulatory and commercialization milestone that expands the company’s access to the U.S. oncology-care market.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.72
More News
- Taiwan benchmark Taiex rises to record intraday high as tech stocks advance
- AMD joins the $1 trillion club as chip rally surges - our AI Strategy saw it early
- Paramount agrees invest $1.5 billion in domestic movies and create a board for editorial independence at CNN, CBS as part of deal for Warner Bros.
- Paramount and state AGs will settle lawsuit, allowing Warner Bros. merger to proceed, reports say
- Here's who we know is going to the Trump-Xi dinner so far
- +17% in a single session: This AI-picked stock catches a data-center breakout
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Index and ETF Holdings Data for AI Research
- Capital Intensity as Gravity: The AI Trade Enters Its Industrial Era (Looking at Q3 2025 Earnings in Tech)